Real-Life Effectiveness and Safety of Upadacitinib in Adults…
Established
31
Citations19
Refs2023
Year
Search Works
Work Details
- DOI 10.1007/s13555-022-00882-z
- PMID https://pubmed.ncbi.nlm.nih.gov/36617589
- PMCID https://www.ncbi.nlm.nih.gov/pmc/articles/9827011
- OpenAlex ID W4313812356
- Type Article
- Language EN
- Published 09 Jan 2023
- Volume 13 (2)
- Pages 651–660
- Source Dermatology and Therapy
- Publisher Adis, Springer Healthcare
- FWCI 8.59
- Countries 1
- Institutions 2
- Added 09 Jan 2023
- Updated 28 Oct 2026
External Links
MENU
0
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study
Article 2023 EN Gold
INTRODUCTION: The treatment of severe atopic dermatitis (AD) includes cyclosporine and recently approved biologics and small molecules. Among these, upadacitinib is a selective inhibitor of Janus kinase 1, approved for the treatment of severe AD in adolescents/adults. Upadacitinib has shown efficacy and safety in several phase 3 clinical trials, but data on real-life patients are still lacking. ME…
31
Citations
19
References
7
Authors
8.59
FWCI
Citations by Year
Last 4 yearsTopics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
7 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Luigi Gargiulo | Humanitas University (IT) IRCCS Humanitas Research Hospi… (IT) | |
| 2 | Luciano Ibba Corresponding | Humanitas University (IT) IRCCS Humanitas Research Hospi… (IT) | |
| 3 | Andrea Cortese | Humanitas University (IT) IRCCS Humanitas Research Hospi… (IT) | |
| 4 | Jessica Avagliano | IRCCS Humanitas Research Hospi… (IT) | |
| 5 | Mario Valenti | Humanitas University (IT) IRCCS Humanitas Research Hospi… (IT) | |
| 6 | Antonio Costanzo | Humanitas University (IT) IRCCS Humanitas Research Hospi… (IT) | |
| 7 | Alessandra Narcisi | IRCCS Humanitas Research Hospi… (IT) |
Related Works
10Data: OpenAlex